Segment Reporting - Segment information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Segment Reporting
Grant and award revenue	$ 2,169		$ 2,660	$ 966
Total research and development expenses	6,394	$ 8,475	11,823	16,491
Total general and administrative expenses	2,619	3,439	5,872	6,617
Total operating expenses	9,013	11,914	17,695	23,108
Operating loss	(6,844)	(11,914)	(15,035)	(22,142)
Other income (expense), net	(9,451)	20,900	(7,791)	6,107
Net income (loss)	(16,295)	8,986	(22,826)	(16,035)
Single Reportable Segment
Segment Reporting
Grant and award revenue	2,169		2,660	966
Expenses not allocated by projects	592	544	1,112	1,176
Total external research and development expenses	1,770	3,502	2,514	6,155
Research and development personnel expenses	2,293	2,809	4,606	5,422
Other research and development expenses	2,331	2,164	4,703	4,914
Total research and development expenses	6,394	8,475	11,823	16,491
General and administrative personnel expenses	1,191	1,571	2,592	2,505
Other general and administrative expenses	1,428	1,868	3,280	4,112
Total general and administrative expenses	2,619	3,439	5,872	6,617
Total operating expenses	9,013	11,914	17,695	23,108
Operating loss	(6,844)	(11,914)	(15,035)	(22,142)
Other income (expense), net	(9,451)	20,900	(7,791)	6,107
Net income (loss)	(16,295)	8,986	(22,826)	(16,035)
Single Reportable Segment | AP-PA02: Non-Cystic Fibrosis Bronchiectasis
Segment Reporting
External research and development expenses	152	1,768	(288)	3,602
Single Reportable Segment | AP-PA02: Cystic Fibrosis
Segment Reporting
External research and development expenses	14	138	25	235
Single Reportable Segment | AP-SA02: Bacteremia
Segment Reporting
External research and development expenses	1,011	1,051	1,663	1,134
Single Reportable Segment | AP-SA02Prosthetic Joint Infection
Segment Reporting
External research and development expenses	$ 1	$ 1	$ 2	$ 8